Heterocyclic Building Blocks-isoxazole

Wang, Ze-bo published the artcileApplication of parecoxib sodium combined with fentanyl in surgery of nucleus pulposus of lumbar intervertebral disc, Computed Properties of 198470-85-8, the publication is Xiandai Zhenduan Yu Zhiliao (2016), 27(10), 1801-1803, database is CAplus.

Objective: To analyze the effect of parecoxib sodium combined with fentanyl in surgery of nucleus pulposus of lumbar intervertebral disk, so as to provide reference for clin. anesthesia. Methods: A total of 78 patients undergoing surgery of nucleus pulposus of lumbar intervertebral disk in our hospital from July 2014 to Feb. 2015 were selected as the research subjects, and were divided into a study group and a control group, according to the time of admission. Patients in the study group took parecoxib sodium combined with fentanyl for analgesia, and patients in the control group took fentanyl for analgesia. The analgesia before anesthesia (T₀), needle piercing the back skin (T₁), disk fibrosis edge (T₂), window opening (T₃), nucleus pulposus removal (T₄), and radiofrequency ablation time (T₅) was analyzed. Results: At T₀, there were no significant differences in MAP (mean arterial pressure), HR (heart rate) or SpO₂ (blood oxygen saturation), and no significant difference in VAS scores (P > 0.05). At T₁-T₅, the MAP of the study group was significantly lower than that of the control group (P < 0.05). At T₁-T₅, the HR of the study group was significantly lower than that of the control group (P < 0.05), and the SpO₂ of the two groups did not change significantly (P > 0.05). At T₁-T₅, the VAS score of the study group was significantly lower than that of the control group (P < 0.05). The incidence (15.4%) of addnl. drugs in the study group was significantly lower than that (35.9%) in the control group (P < 0.05). There were no adverse reactions such as nausea or lethargy in the two groups of patients during treatment and after surgery. Conclusion: The use of parecoxib sodium combined with fentanyl in patients undergoing surgery of nucleus pulposus of lumbar intervertebral disk has a good analgesic effect and can reduce the dosage of fentanyl, which has practical value.

Xiandai Zhenduan Yu Zhiliao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C26H26N4O7, Computed Properties of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liang, Shujun published the artcileEffect of sequential celecoxib with parecoxib sodium on perioperative analgesia and joint function recovery of total hip replacement, SDS of cas: 198470-85-8, the publication is Hebei Yixue (2015), 21(11), 1869-1872, database is CAplus.

Objective: To observe and explore the analgesic effect of sequential celecoxib with parecoxib sodium during unilateral total hip arthroplasty (THR) during perioperative period, and to compare with the effect of tramadol. Methods: A total of 102 unilateral THR patients selected from 2011 to May 2014 were randomly divided into a study group (52 cases) and a control group (50 cases). In the study group, 40 mg parecoxib sodium was injected i.v. 30 min before anesthesia induction, and THR surgery was performed after routine anesthesia, analgesia pump was routinely used for analgesia for 2 days after surgery, and 40 mg parecoxib sodium was injected i.v. 3 h after surgery, 2 times/d, for consecutive days, and on the 3rd postoperative day, the celecoxib capsules were taken orally at 200 mg twice a day until discharged. In the control group, 100 mg tramadol injection was injected, and on the 3rd postoperative day, tramadol tablets were taken orally, and other analgesic regimens during the perioperative period were the same as the study group. The visual analog pain (VAS) score and passive active Harris hip score were compared in the perioperative resting state between the two groups. Adverse drug reactions were recorded during analgesia. Results: Within 24 h after operation, the number of analgesia pump compressions in the study group (10.2 ± 3.5) was significantly less than that in the control group (15.8 ± 5.5) (u = 6.108, P < 0.001). The VAS scores at 12 h, 24 h, 48 ??hours, 72 h, and 96 h in the study group were significantly lower than those in the control group (P < 0.05). The Harris hip scores at 7 and 14 days after surgery in both groups were significantly improved compared with those before surgery. The scores at 7 and 14 days after surgery in the study group were significantly higher than those in the control group (P < 0.05). The perioperative nausea, vomiting, dizziness, drowsiness, urinary retention and other adverse drug reactions in the study group were lower than those in the control group, without statistically significant difference (P > 0.05). Conclusion: Sequential celecoxib with parecoxib sodium during THR during perioperative period can significantly reduce the pain of patients, reduce the dose of opioids in the analgesia pump, and help patients to exercise hip function as soon as possible, and has low incidence of the adverse reactions compared with tramadol.

Hebei Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, SDS of cas: 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Jun published the artcileInfluences of parecoxib sodium on pulmonary oxygenation function in patients after valve replacement under cardiopulmonary bypass, Computed Properties of 198470-85-8, the publication is Jilin Yixue (2014), 35(34), 7638-7640, database is CAplus.

The influences of parecoxib sodium on pulmonary oxygenation function in patients after valve replacement under cardiopulmonary bypass (CPB) were evaluated. Sixty-three patients suffering from valve replacement under CPB were collected and divided into three groups: the control group (group I), parecoxib sodium 20 mg group (group II) and parecoxib sodium 40 mg group (group III). The changes of end-tidal CO2 pressure (P_ETCO₂), arterial O₂ concentration (CaO₂), pulmonary alveolar-arterial O₂ pressure (PA-aO₂), oxygenation index (OI), spontaneous breathing frequency and ventilator assisted ventilation time in these patients were observed and compared. In group I, the levels of PA-aO₂ and OI after surgery were significantly increased as compared before surgery. And the levels of PA-aO₂ and OI in group III were significantly lower than those in group I and group II. The most stable spontaneous breathing frequency and the lowest incidence rate of dry/moist rales were observed in group III. It indicated that parecoxib sodium had protective effects on pulmonary injury and oxygenation function improvement in patients after valve replacement under CPB.

Jilin Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Computed Properties of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Jurberg, Igor D. published the artcileAn Aminocatalyzed Stereoselective Strategy for the Formal α-Propargylation of Ketones, Category: isoxazole, the publication is Chemistry – A European Journal (2017), 23(41), 9716-9720, database is CAplus and MEDLINE.

A two-step reaction sequence is described for the asym. formal α-propargylation of ketones. This approach takes advantage of an aminocatalyzed conjugate addition of ketones to alkylidene isoxazol-5-ones, followed by a controlled nitrosative degradation event. The target compounds can be accessed in broad scope, in moderate to good yields, perfect diastereocontrol and good to excellent enantioselectivity.

Chemistry – A European Journal published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C9H7NO2, Category: isoxazole.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Chen, Li published the artcileAnalysis of effect of oxycodone hydrochloride combined with parecoxib sodium on hyperalgesia after remifentanil combined anesthesia surgery, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Xiandai Zhenduan Yu Zhiliao (2017), 28(13), 2436-2437, database is CAplus.

To study the effect of oxycodone hydrochloride combined with parecoxib sodium on hyperalgesia after remifentanil combined anesthesia surgery. Eighty patients with remifentanil combined anesthesia were selected and randomly divided into group I and group II. Group I received combined remifentanil anesthesia alone, and group II received oxycodone hydrochloride combined with parecoxib sodium. The incidence of adverse reactions such as chills and restlessness, pain score at 0.5-4h postoperatively, and differences in breathing recovery time, extubation time, remifentanil and propofol dosages were compared between the two groups. Compared with group I, the incidence of adverse reactions such as chills and agitation was lower in group II (P < 0.05). The pain score in group II was lower at 0.5-4h after operation (P < 0.05). The breathing recovery time, extubation time, and the dosage of remifentanil and propofol were similar in the two groups (P > 0.05). Oxycodone hydrochloride combined with parecoxib sodium has a great impact on hyperalgesia after remifentanil combined anesthesia surgery, which can effectively play an analgesic effect, reduce postoperative hyperalgesia, and reduce postoperative agitation and other complications.

Xiandai Zhenduan Yu Zhiliao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Wang, Liang published the artcilen-Bu₄NI-catalyzed direct amination of ethers with aryl tetrazoles and triazoles via cross-dehydrogenative coupling reaction, HPLC of Formula: 2251-79-8, the publication is Catalysis Science & Technology (2015), 5(5), 2891-2896, database is CAplus.

An efficient, metal-free protocol for direct amination of ethers with aryl tetrazoles and triazoles has been developed using tetrabutylammonium iodide (TBAI) as a catalyst and tert-Bu hydroperoxide (t-BuOOH) as an oxidant. A series of ethers, aryl tetrazoles as well as triazoles are tolerated in this system, giving the corresponding products in moderate to good yields.

Catalysis Science & Technology published new progress about 2251-79-8. 2251-79-8 belongs to isoxazole, auxiliary class Trifluoromethyl,Fluoride,Benzene, name is 5-(4-(Trifluoromethyl)phenyl)-1H-tetrazole, and the molecular formula is 0, HPLC of Formula: 2251-79-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Wang, Liang published the artcileTransition-Metal-Free Direct Alkylation of Aryl Tetrazoles via Intermolecular Oxidative C-N Formation, Application In Synthesis of 2251-79-8, the publication is Journal of Organic Chemistry (2014), 79(23), 11780-11786, database is CAplus and MEDLINE.

A transition-metal-free synthetic approach for constructing alkylated aryl tetrazoles has been developed using n-Bu₄NI as the catalyst and t-BuOOH as the oxidant. It involves the direct C-N bond formation through sp³ C-H activation. A wide range of benzylic C-H substrates (or alkyl ethers) and aryl tetrazoles undergo this reaction smoothly to deliver the corresponding products, e.g., I, in good yields.

Journal of Organic Chemistry published new progress about 2251-79-8. 2251-79-8 belongs to isoxazole, auxiliary class Trifluoromethyl,Fluoride,Benzene, name is 5-(4-(Trifluoromethyl)phenyl)-1H-tetrazole, and the molecular formula is C5H10Cl3O3P, Application In Synthesis of 2251-79-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Xiao, Wei published the artcileOrganocatalytic Asymmetric Four-Component [5+1+1+1] Cycloadditions via a Quintuple Cascade Process, COA of Formula: C9H7NO2, the publication is Advanced Synthesis & Catalysis (2018), 360(18), 3526-3533, database is CAplus.

An asym. four-component [5+1+1+1] formal cycloaddition reaction of 3-substituted 2-cyclopentenones, activated methylene nucleophiles and two mols. of aldehydes was developed under chiral primary aminocatalysis, producing a diversity of highly enantioenriched fused and spirocyclic frameworks with high mol. complexity. Mechanism studies indicated that the current reaction proceeded in a challenging cascade quintuple Knoevenagel condensation/Michael addition/retro-Michael addition/Michael addition/Michael addition sequence via diverse aminocatalytic modes.

Advanced Synthesis & Catalysis published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C15H21BO2, COA of Formula: C9H7NO2.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhu, Yu published the artcileEfficacy of parecoxib sodium on postoperative shivering: meta-analysis of clinical trials, Name: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Journal of International Medical Research (2018), 46(1), 3-10, database is CAplus and MEDLINE.

Objective: To evaluate the effect of parecoxib on preventing postoperative shivering. Methods: Main outcomes were the relative risk (odds ratio, OR) and 95% confidence interval (CI) relative to the incidence of shivering. Results: Fourteen trials with 1,175 patients were analyzed. The pooled evidence suggested that parecoxib sodium, given before anesthesia or postoperatively (only 4 cases), had the potential to prevent postoperative shivering (OR = 0.21, 95% CI, 0.16, 0.29). Compared with the placebo, parecoxib sodium significantly lowered the incidence of postoperative shivering as follows: mild shivering [OR = 0.51, 95% CI (0.35, 0.74)]; moderate shivering [OR = 0.28, 95% CI (0.18, 0.45)]; severe shivering [OR = 0.18, 95% CI (0.10, 0.33)]. Compared with placebo, there was no significant association of parecoxib sodium with restlessness [OR = 0.95, 95% CI (0.59, 1.52)] or nausea/vomiting [OR = 0.24, 95% CI (0.09, 0.66)]. In addition, pethidine rescue was used significantly more often in the control group than in the parecoxib sodium group [OR = 0.22, 95% CI (0.09, 0.53)]. Conclusions: Parecoxib sodium may be an effective strategy for preventing postoperative shivering.

Journal of International Medical Research published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C13H15NO6S, Name: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liu, Wen-jie published the artcilePaclitaxel-induced lung injury and its amelioration by parecoxib sodium, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Scientific Reports (2015), 12977, database is CAplus and MEDLINE.

To investigate the mechanism of paclitaxel-induced lung injury and its amelioration by parecoxib sodium. In this study, rats were randomly divided into: the control group (Con); the paclitaxel chemotherapy group (Pac); the paclitaxel+ parecoxib sodium intervention group (Pac + Pare); and the parecoxib sodium group (Pare). We observed changes in alveolar ventilation function, alveolar-capillary membrane permeability, lung tissue pathol. and measured the levels of inflammatory cytokines and cyclooxygenase-2 (Cox-2) in lung tissue, the expression of tight junction proteins (Zo-1 and Claudin-4). Compared with the Con group, the lung tissue of the Pac group showed significantly increased expression of Cox-2 protein (p < 0.01), significant lung tissue inflammatory changes, significantly increased expression of inflammatory cytokines, decreased expression of Zo-1 and Claudin-4 proteins (p < 0.01), increased alveolar-capillary membrane permeability (p < 0.01), and reduced ventilation function (p < 0.01). Notably, in Pac + Pare group, i.p. injection of parecoxib sodium led to decreased Cox-2 and ICAM-1 levels and reduced inflammatory responses, the recovered expression of Zo-1 and Claudin-4, reduced level of indicators reflecting the high permeability state, and close-to-normal levels of ventilation function. Intervention by the Cox-2-specific inhibitor parecoxib sodium can block this damage.

Scientific Reports published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem